key: cord-0916580-kbj72qye
authors: Deng, Mingyan; Jiang, Ling; Ren, Yan; Liao, Jiayu
title: Can We Reduce Mortality of COVID-19 if We do Better in Glucose Control?
date: 2020-06-02
journal: Med Drug Discov
DOI: 10.1016/j.medidd.2020.100048
sha: 96acbb100c42446281f7f6ee28b296198d227f29
doc_id: 916580
cord_uid: kbj72qye

The SARS-CoV-2 has infected more than 3 million people and caused more than 240,000 death globally. Among the COVID-19 patients, the prevalence of people with other chronic diseases, such as diabetes, high blood pressure, and coronary heart disease is much higher than others. More strikingly, the survival rate of diabetic patients is also much lower than in non-diabetic patients. In addition to the general damage of high glucose to cells and tissues, a recent discovery that high glucose activates interferon regulatory factor 15 promotes influenza virus -induced cytokine storm. This discovery may shed light on the high incidence of diabetes in COVID-19. Several diabetes prevention strategies together with recent significant data-driven diabetes prediction approaches, which may help COVID-19 treatments, have been proposed.

J o u r n a l P r e -p r o o f Coronaviruses (CoVs) are enveloped, single positive-stranded RNA viruses, which belong to the subfamily Coronavirinae，most of which are transmitted between animals and a few between humans. Two strains of coronaviruses, the severe acute respiratory syndrome CoV (SARS-CoV) and the Middle East respiratory syndrome CoV (MERS-CoV), have caused two out of four pandemics in 21 century 1 . A novel coronavirus, SARS-CoV-2, which causes a severe pulmonary respiratory syndrome, called COVID-19. Since the outbreak of COVID-19, it quickly spreads to more than 200 countries worldwide as an unprecedented global pandemic. As of May 3rd, the global number of confirmed patients has risen to more than 3,563,596, and the death rate has reached 248,135 ( death rate ~ 6.96%) 2 .

Unfortunately, so far, many vaccines are still under development, and we have no specific anti-SARS-CoV-2 drug, although FDA has approved the Remdesvir for treating COVID-19 for an emergency use 3 . The Remdesvir shows treatment benefits by reducing hospitalization time for 31%, but the reduction of the death rate has reduced has not reached statistical significance(8.0% vs.11.6%, 0.059) 4 . On the other hand, some traditional Chinese medicines (TCM) have reported to likely have some effect, and probably can stabilize symptoms and avoid aggravation, such as qingfei paidu decoction (QPD) 5 .

Understanding the clinical characteristics of mild and severe COVID-19 patients and the associated factors associated with the non-survivor will help us reduce the death rate. The clinical spectrum of COVID-19 ranges from mild, moderate, severe to critical conditions. Some patients show symptoms like a common cold, while others have severe lower airways symptoms and die. The most common COVID-19 symptoms were fever, fatigue, dry cough, and in a small number of patients, and very often, these symptoms were accompanied by nausea, vomiting, and diarrhea 6,7 . Male seems like more predominant in deceased patients than in recovered patients 8, 9 . Most severe cases and non-survivor with COVID-19 have occurred in patients with comorbidities, particularly hypertension, cardiovascular disease (CVDs), diabetes mellitus, and obstructive pulmonary disease 6,8-10 . For patients with diabetes and other chronic primary diseases, the probability of suffering from COVID-19 is higher, the condition is more severe after infection, and the prognosis is poor 11,12 . Patients with diabetes or hypertension had J o u r n a l P r e -p r o o f a 2-fold increase in the risk of severe disease or requiring intensive care unit (ICU) admission 13 .

More strikingly, the diabetes rate is much higher in the non-survivor than survivors(34%vs.14%) 8 . Globally, approximately 20-50% of COVID-19 patients have diabetes, much higher than the diabetes incidence rate in the world 14 . A recent CNN reported that novel coronavirus pneumonia patients generally have one or more underlying diseases in the most extensive health care system in New York, including the highest mortality rate among diabetics 15 . In their study, novel coronavirus pneumonia patients have a higher risk of fatal diabetes than 50% without diabetes.

Diabetes is also a risk factor for many other epidemic diseases, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome(MERS) 16, 17, 18, 19, 20 . The odds ratio of developing severe or lethal disease following MERS-CoV infection with comorbid diabetes ranges from 2.47 to 7.24. Compared with others, diabetes patients, severe infection, the mortality rate, ICU care, and the need for mechanical ventilation were 3.0-3.3 times higher in people with diabetes than in nondiabetic patients with the severe acute respiratory syndrome (SARS) 21, 22 . The number of complication patients with influenza A (H1N1) admitted to an intensive care unit is 4.29 times that of nondiabetic 23 . Diabetes is likely to cause a dysregulated immune response in MERS cases, resulting in more severe and prolonged lung pathology. The same mechanism seems to occur in COVID-19. The following factors may cause a high mortality risk of COVID-19 with diabetes. First, the level of blood glucose control directly affects the immune response and state of the body. Diabetic patients have low immunity and are prone to increase the risk of disease. Once infected, it is likely to aggravate the condition of diabetic patients further, increase the difficulty of blood glucose control, and more easily aggravate the infection, thus leading to cytokine storm and acute inflammatory response. Inflammation is closely related to the occurrence and development of diabetes 24, 25 . A clinical study found that COVID-19 patients without other comorbidities but with diabetes had higher serum levels of inflammation-related biomarkers such as IL-6 and were susceptible to a cytokine storm, leading to rapid ACE2 is also expressed in islet cells. SARS-CoV-2 is likely to infect islet cells through the ACE2 receptor, affecting and destroying islet function and aggravating the imbalance of blood glucose metabolism 23 . Therefore, it is speculated that the pancreas may also be the target organ of SARS-CoV-2. The disease factor of blood glucose rise in patients with COVID-19 may be the high combination of SARS-CoV-2 and ACE2 receptor in islet cells, leading to islet cell damage. The virus infection symptoms and diabetes affect each other and aggravate each other, leading to further deterioration of the condition 20, 23 . Third, medication also harms the control of blood glucose levels in J o u r n a l P r e -p r o o f COVID-19 with diabetic patients. If glucocorticoid is used, blood sugar will rise, hyperosmotic dehydration, ketoacidosis, and even death may occur 27 . The application of the protease inhibitor Lopinavir/Ritonavir can damage the insulin signal transduction system in the peripheral tissues, and damage the islet β cells by changing the glucose and lipid metabolism eventually leads to insulin resistance and diabetes 28, 29 . Tangzhiping granule, Shenzhu Tiaopi granule (SZTP) and Qiweitangping capsule). These studies showed that 12-36 months of TCM intervention significantly reduced the relative risk of prediabetes progression to T2D by 32.1-83.5% 35 . The excellent outcomes make TCM a possible preventive method for diabetes 34, 36 .

Up to now, there are several models using bigdata that predict the risk of diabetes. K Chien et al constructed a simple point model using Cox regression coefficients, established a 10-year diabetes incidence model applicable to the Chinese population with an AUC of 0.702, which is better than traditional prediction models such as Framingham model 37 . Jianfeng Zhang et al. developed a diabetes diagnosis method based on a standardized tongue image using a support vector machine (SVM), which also has good predictive power 38 . However, neither of them can answer the most appropriate period of intervention for people who are at high risk. Previous research has shown that there is a critical transition period before the onset of diabetes 39 , and this critical transition period may be the most appropriate time to prevent diabetes. We aim to establish models that can discriminate individuals in critical transition, and intervention can be applied to prevent diabetes and, therefore, contribute to reducing COVID-19 mortality.

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

A new coronavirus associated with human respiratory disease in China

Diabetes and the severity of pandemic influenza A (H1N1) infection

Pathogenesis of Middle East respiratory syndrome coronavirus

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Inflammation and metabolic disorders

O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5

Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review

HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4

Adiponectin and leptin in Afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes

REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN

The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study

Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study

Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)

Chinese herbal medicine Tianqi reduces progression from impaired glucose tolerance to diabetes: a double-blind, randomized, placebo-controlled, multicenter trial

Evidence and potential mechanisms of traditional Chinese medicine for the treatment of type 2 diabetes: A systematic review and meta-analysis

Clinical research of traditional Chinese medical intervention on impaired glucose tolerance

A prediction model for type 2 diabetes risk among Chinese people

Diagnostic Method of Diabetes Based on Support Vector Machine and Tongue Images

Defining and characterizing the critical transition state prior to the type 2

We would like to thank the 135 grant from Huaxi Hospital for the support and the National Natural Science Foundation of China (Grant No. 81503464) to JLing.

J o u r n a l P r e -p r o o f